Jenburkt Pharmaceuticals — 360° view

Jenburkt Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹48 crore and net profit of ₹10 crore for the September 2026 quarter.

Jenburkt Pharmaceuticals (NSE: JENBURPH) closed at ₹893.20 on 20 Nov 2026. Its market capitalisation is ₹394 crore and it trades at 11.0 times earnings.

Share price
₹893.20 (20 Nov 2026)
Market cap
₹394 Cr (20 Nov 2026)
P/E
11.02 (20 Nov 2026)
Revenue
₹48 Cr (September 2026 quarter)
Net profit
₹10 Cr (September 2026 quarter)
ROCE
27.0% (FY26)
ROE
20.2% (FY26)
Book value
₹464 (FY26)
Dividend yield
2.32% (last 12 months to 20 Nov 2026)
52-week high / low
₹1,073.90 / ₹845.00 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: JENBURPH

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.